Pluri (PLUR)

• Market cap: $27.4M
• 1 day: -2.63%
• 5 days: -12.68%
• 1 month: -18.9%
• 3 months: -39.47%
• 6 months: -30.35%
• Year to date: -31.64%
• 1 year: -36.34%
• 5 years: -93.78%
• 10 years: -96.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Employees: 142